Tauopathies as clinicopathological entities. Irwin, D. J. Parkinsonism & Related Disorders, 22 Suppl 1:S29–33, January, 2016.
doi  abstract   bibtex   
Tauopathies are a class of neurodegenerative disorders characterized by neuronal and/or glial inclusions composed of the microtubule-binding protein, tau. Several lines of evidence suggest tau aggregation is central to the neurodegenerative process in tauopathies. First, recent animal and cell model studies find abnormally-modified tau alone may be transmitted between adjacent neurons and spread to anatomically connected brain regions to recapitulate human disease. Further, staging efforts in human autopsy cases suggest a sequential distribution of tau aggregation in the central nervous system that could reflect this observed cell-to-cell transmission of pathogenic tau species in animal models. Finally, pathogenic mutations in the MAPT gene encoding tau protein cause hereditary forms of tauopathy. Clinically, tauopathies can present with a range of phenotypes that include both movement- and cognitive/behavioral-disorders (i.e. frontotemporal dementia spectrum disorders) or non-specific amnestic symptoms in advanced age. A major limitation is that current clinical diagnostic criteria for these disorders do not reliably differentiate underlying tauopathy from other neurodegenerative diseases, such as TDP-43 proteinopathies. Thus, current research efforts are focused on improving the ante mortem diagnosis of tauopathies, including pre-clinical stages of disease, as many therapeutic strategies for emerging disease-modifying therapies focus on preventing abnormal folding and spread of tau pathology.
@article{irwin_tauopathies_2016,
	title = {Tauopathies as clinicopathological entities},
	volume = {22 Suppl 1},
	issn = {1873-5126},
	doi = {10.1016/j.parkreldis.2015.09.020},
	abstract = {Tauopathies are a class of neurodegenerative disorders characterized by neuronal and/or glial inclusions composed of the microtubule-binding protein, tau. Several lines of evidence suggest tau aggregation is central to the neurodegenerative process in tauopathies. First, recent animal and cell model studies find abnormally-modified tau alone may be transmitted between adjacent neurons and spread to anatomically connected brain regions to recapitulate human disease. Further, staging efforts in human autopsy cases suggest a sequential distribution of tau aggregation in the central nervous system that could reflect this observed cell-to-cell transmission of pathogenic tau species in animal models. Finally, pathogenic mutations in the MAPT gene encoding tau protein cause hereditary forms of tauopathy. Clinically, tauopathies can present with a range of phenotypes that include both movement- and cognitive/behavioral-disorders (i.e. frontotemporal dementia spectrum disorders) or non-specific amnestic symptoms in advanced age. A major limitation is that current clinical diagnostic criteria for these disorders do not reliably differentiate underlying tauopathy from other neurodegenerative diseases, such as TDP-43 proteinopathies. Thus, current research efforts are focused on improving the ante mortem diagnosis of tauopathies, including pre-clinical stages of disease, as many therapeutic strategies for emerging disease-modifying therapies focus on preventing abnormal folding and spread of tau pathology.},
	language = {eng},
	journal = {Parkinsonism \& Related Disorders},
	author = {Irwin, David J.},
	month = jan,
	year = {2016},
	pmid = {26382841},
	pmcid = {PMC4662611},
	keywords = {Animals, Argyrophilic grain disease, Brain, Corticobasal degeneration, Corticobasal syndrome tauopathy, DNA-Binding Proteins, Frontotemporal dementia, Frontotemporal lobar degeneration, Humans, MAPT mutation, Neurodegenerative Diseases, Pick Disease of the Brain, Pick's disease, Primary age related tauopathy, Primary progressive aphasia, Progressive supranuclear palsy, Tauopathies, tau Proteins},
	pages = {S29--33},
}

Downloads: 0